Key result
TG2 knockdown reduces HCC cell proliferation and alters signaling independently of EMT.
Why the study?
The molecular mechanisms by which transglutaminase 2 contributes to hepatocellular carcinoma malignancy were unclear.
Does TG2 knockdown reduce cell proliferation and alter signaling pathways in hepatocellular carcinoma cells?
Does TG2 knockdown reduce cell proliferation and alter signaling pathways in hepatocellular carcinoma cells?
TG2 contributes to hepatocellular carcinoma malignancy by stimulating cell proliferation signaling pathways independently of epithelial-mesenchymal transition.
Answers are grounded in this paper and cite their sources.
TG2 knockdown may curb HCC proliferation via PI3K-Akt independently of EMT; leaves open whether targeting TG2 improves outcomes.
Transglutaminase 2 (TG2) is a multifunctional protein and plays a role in cancer progression. We previously identified TG2 as an early-recurrence biomarker in hepatocellular carcinoma (HCC). TG2-knockdown (shTG2) and control (shCtl) HCC cell lines were used for comparative analyses to clarify the molecular mechanisms underlying the contribution of this protein to HCC malignancy. The proliferation of shTG2 cells was slightly but significantly decreased compared with that of shCtl cells. Differential gene expression profiling based on GeneChip arrays revealed the enrichment of the PI3K-Akt signaling pathway and showed that the expression of Dickkopf-1 and -3 (DKK1 and DKK3, respectively), inhibitors and modulators of the Wnt/β-catenin signaling pathway, was increased in shTG2 cells. The expression of epithelial-mesenchymal transition (EMT)-related genes was similar in both shCtl and shTG2 cells before and after TGF-β1 treatment, even though TGF-β1 markedly upregulated TG2. Thus, TG2 may contribute to cancer malignancy via the stimulation of cell proliferation signaling, such as PI3K-Akt and Wnt/β-catenin signaling, but not EMT. This effect might be further enhanced by humoral factors such as TGF-β1 from the tumor microenvironment.
No takes yet. Share an insight, caveat, or question.
Yamaguchi et al. (2025) studied Hepatocellular carcinoma (n=366). Transglutaminase 2 (TG2) knockdown vs. Control (shCtl) cells was evaluated on Cell proliferation (p=<0.0001). Transglutaminase 2 knockdown significantly reduced cell proliferation in hepatocellular carcinoma cells and modulated signaling pathways independently of epithelial-mesenchymal transition.
Synapse has enriched 10 related papers. Consider them for comparative context: